Hemogenyx Pharmaceuticals has announced encouraging progress in its Phase I clinical trial of HG-CT-1, a CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia (AML) in adults.
Hemogenyx Pharma Plc (LON:HEMO) Awarded G-Rex® Grant to Support Scalable, Cost-Optimized CAR-T Manufacturing
Hemogenyx Pharmaceuticals Awarded G-Rex® Grant to Support Scalable, Cost-Optimized CAR-T Manufacturing
Hemogenyx Pharma Plc (LON:HEMO) Second Patient Passes Initial Safety Tests
Second Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation
Hemogenyx Pharma Plc (LON:HEMO) First-in-Human leukaemia treatment with HG-CT-1
First-in-Human Treatment with HG-CT-1 for Relapsed or Refractory Acute Myeloid Leukemia
Hemogenyx Pharma Plc (LON:HEMO) IRB Approval for Phase I Clinical Trial
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)
Hemogenyx Pharma Plc (LON:HEMO) CBR Brain Delivery
Chimeric Bait Receptors for Combatting Brain Cancers and Neurodegenerative Diseases Can Be Delivered via Programmed Microglial Cells